Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease vascular disease
Phenotype C0011860|type 2 diabetes mellitus
Sentences 53
PubMedID- 24278703 Finally, the results of the accord trial showed that the combination of fenofibrate and simvastatin does not reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus, as compared with statin monotherapy [78]; only subgroups of patients with dyslipidemia seem to benefit from fibrate therapy.
PubMedID- 20047560 Dyslipidaemia contributes to endothelial dysfunction and cvd (cardiovascular disease) in type 2 diabetes mellitus.
PubMedID- 26083376 Pioglitazone has shown to have beneficial effect on cardiovascular diseases in patients with type 2 diabetes mellitus [18–20].
PubMedID- 20228404 Background: we investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus who were at high risk for cardiovascular disease.
PubMedID- 25214836 Left ventricular hypertrophy (lvh) and albuminuria are both markers for cardiovascular diseases (cvds) in patients with type 2 diabetes mellitus (t2dm).
PubMedID- 25554536 Effect of statin therapy on incident type 2 diabetes mellitus in patients with clinically manifest vascular disease.
PubMedID- 20040043 [37] to suggest that rosiglitazone may contribute to a decrease in the development of vascular diseases associated with type 2 diabetes mellitus through actions on pecam-1.
PubMedID- 21390057 Pulse pressure and systolic night-day ratio interact in prediction of macrovascular disease in patients with type 2 diabetes mellitus.
PubMedID- 24602748 [primary prevention of cardiovascular disease with statin in type 2 diabetes mellitus: is it time to change our strategy.
PubMedID- 26246173 Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the american heart association and the american diabetes association.
PubMedID- 24579534 Pattern of dyslipidemia and evaluation of non-hdl cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus.
PubMedID- 19232762 Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials.
PubMedID- 24855344 Several large-scale, prospective, randomized trials have documented that lowering glycemic levels can prevent the development of microvascular disease in people with type 2 diabetes mellitus (t2dm).
PubMedID- 23466074 Role of relationship between hba1c, fibrinogen and hdl-cholesterol on cardiovascular disease in patients with type 2 diabetes mellitus.
PubMedID- 24076532 (presence of macrovascular disease in type 2 diabetes mellitus; nct00298844).
PubMedID- 22338075 Associations between exponential childhood growth superimposed on low birth weight and adult onset cardiovascular disease with glucose intolerance/type 2 diabetes mellitus exist in epidemiological investigations.
PubMedID- 20934769 Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus.
PubMedID- 20580779 Our results suggested that incorporation of almonds into a healthy diet has beneficial effects on adiposity, glycemic control, and the lipid profile, thereby potentially decreasing the risk for cardiovascular disease in patients with type 2 diabetes mellitus.
PubMedID- 26395643 Coenzyme q10 and oxidative stress, the association with peripheral sensory neuropathy and cardiovascular disease in type 2 diabetes mellitus.
PubMedID- 22440125 Microalbuminuria is one of the strongest predictors of both adverse renal and cardiovascular disease (cvd) outcomes in patients with type 2 diabetes mellitus.
PubMedID- 21955281 Background: type 2 diabetes mellitus increases the risk of atherosclerotic cardiovascular disease.
PubMedID- 22285702 We investigated the effect of rhr on the incidence of type 2 diabetes mellitus (t2dm) in patients with clinically manifest vascular diseases.
PubMedID- 20550659 The action to control cardiovascular risk in diabetes (accord) study investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus who were at high risk for cardiovascular disease [1].
PubMedID- 24918803 Interventions targeted at modifiable risk factors, such as smoking cessation and management of hypertension and dyslipidemia, reduce the risk of cardiovascular disease (cvd) in patients with type 2 diabetes mellitus (t2dm).
PubMedID- 24920930 Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.
PubMedID- 21398276 Circulating angiopoietic cells and diabetic retinopathy in type 2 diabetes mellitus, with or without macrovascular disease.
PubMedID- 19875998 The impact of obesity on cardiovascular disease (cvd) outcomes in patients with type 2 diabetes mellitus (t2dm) and established coronary artery disease (cad) is controversial; whether bmi and/or waist circumference correlate with atherothrombotic risk factors in such patients is uncertain.
PubMedID- 25212259 Development of a prediction model for fatal and non-fatal coronary heart disease and cardiovascular disease in patients with newly diagnosed type 2 diabetes mellitus: the basque country prospective complications and mortality study risk engine (bascore).
PubMedID- 25815676 Glucagon-like peptide-1 (glp-1) has been demonstrated to play an important role in type 2 diabetes mellitus, leading to cardiovascular diseases.
PubMedID- 25708055 This study aimed to assess the effects of active and passive smoking exposure on the development of cardiovascular disease in patients with type 2 diabetes mellitus.
PubMedID- 20847892 Evidence suggests that the maintenance of a large muscle mass may reduce metabolic risk factors—namely, obesity, dyslipidaemia, and type 2 diabetes mellitus—associated with cardiovascular disease [13–15].
PubMedID- 26089896 The results of this study indicated unfavorable upward trends in serum lipid levels and in the prevalence of dyslipidemia, chd, and cerebrovascular disease among patients with newly diagnosed type 2 diabetes mellitus in the southwest chinese han population.
PubMedID- 21625418 The goal for non-hdl cholesterol has been reported to be the level of ldl cholesterol plus 30 mg/dl.36 in type 2 diabetics, several characteristics such as elevated triglycerides, decreased hdl cholesterol, and elevated small dense ldl, are well-known.25 because non-hdl cholesterol reflects all apolipoprotein b-containing atherogenic lipoproteins, non-hdl cholesterol may be useful in predicting cardiovascular disease in patients with type 2 diabetes mellitus.
PubMedID- 19859073 The burden of microvascular disease in patients with type 2 diabetes mellitus continues to escalate worldwide.
PubMedID- 26246459 Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the american heart association and the american diabetes association.
PubMedID- 26116592 Plasma adiponectin levels inversely correlate to clinical parameters in type 2 diabetes mellitus patients with macrovascular diseases.
PubMedID- 23466101 Objectives: low levels of blood adiponectin contribute to an increased risk of cardiovascular disease (cvd) in patients with type 2 diabetes mellitus (t2dm).
PubMedID- 22430605 In view of the high incidence of macrovascular diseases in patients with type 2 diabetes mellitus and microalbuminuria, the study evaluates the association of microalbuminuria with fasting plasma apo b48 levels, a marker of the residual presence of intestinally derived trls lipoproteins, thought to be highly atherogenic.
PubMedID- 26244041 A recent review identified twelve risk equations for the prediction of cardiovascular disease in subjects with type 2 diabetes mellitus (t2dm) [6].
PubMedID- 21963020 Preliminary evidence in support of fruit intake for the prevention of cardiovascular disease in patients with type 2 diabetes mellitus (t2dm) is still limited.
PubMedID- 25238222 What is it about very low density lipoproteins (vldl) and cardiovascular disease in patients with type 2 diabetes mellitus: is it the triglycerides or the cholesterol.
PubMedID- 23227510 [a current model for predicting the risk of cardiovascular diseases in patients with type 2 diabetes mellitus].
PubMedID- 25251664 Patient empowerment programme in primary care reduced all-cause mortality and cardiovascular diseases in patients with type 2 diabetes mellitus: a population-based propensity-matched cohort study.
PubMedID- 21933841 Purpose: to evaluate myocardial microvascular disease in patients with type 2 diabetes mellitus (dm) using myocardial contrast echocardiography (mce) and to report on its diagnostic accuracy using single photon emission tomography (spect) as reference test.
PubMedID- 25923078 type 2 diabetes mellitus patients with cardiovascular disease showed higher expression of plasma retinol binding protein and glutathione peroxidase-3 compared to those without cardiovascular disease and non-diabetic controls.
PubMedID- 25256018 Aims: this study aimed to investigate the impact of early-onset diabetes on the risk of microvascular diseases in chinese with type 2 diabetes mellitus (t2dm).
PubMedID- 24567354 Increased white blood cell (wbc) count is related to cardiovascular disease in patients with type 2 diabetes mellitus; raised neutrophil lymphocyte ratio (nlr) is associated with metabolic syndrome.
PubMedID- 25527522 Conclusions: in our series, type 2 diabetes mellitus patients with cardiovascular disease at baseline present with an increased risk of developing diabetic peripheral neuropathy at 10 years of follow-up.
PubMedID- 26130877 Winners in each category were as follows: best fellow poster, "diet pattern and cardiovascular disease among women with type 2 diabetes mellitus," by hyun joon shin, md; best resident poster, "oral squamous cell carcinoma: current concepts in imaging, staging, and fibular osteocutaneous free-flap reconstruction," by r.
PubMedID- 24465050 And, would monotherapy with either or both of those drugs reduce the risk of cardiovascular disease events in patients with type 2 diabetes mellitus?

Page: 1 2